| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/01/1999 | WO1999019491A3 Human dnax interleukin-40 (dil-40) |
| 07/01/1999 | WO1999018909A9 Interferon-gamma regulatory factors |
| 07/01/1999 | WO1999018801A9 Methods and compositions for the treatment of autoimmune disease using heat shock proteins |
| 07/01/1999 | WO1999012962A8 Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerases |
| 07/01/1999 | WO1999011292A3 Compositions and methods for treating arthritis utilizing gene therapy |
| 07/01/1999 | WO1999010487A3 Novel transcriptional regulators and uses therefor |
| 07/01/1999 | DE19857904A1 Verfahren zur gezielten Immobilisierung des Thrombogeneseinhibitors Hirudin auf Polymeroberflächen Method for the selective immobilization of Thrombogeneseinhibitors hirudin on polymer surfaces |
| 07/01/1999 | DE19757984A1 Regulatorische DNA-Sequenzen aus der 5'-Region vom Gen der humanen katalytischen Telomerase-Untereinheit udn deren diagnostische und therapeutische Verwendung Regulatory DNA sequences from the 5 'region of the gene of human telomerase catalytic subunit UDN their diagnostic and therapeutic use |
| 07/01/1999 | DE19757250A1 Insulin-like growth factor binding protein und seine Verwendung Insulin-like growth factor binding protein and its use |
| 07/01/1999 | DE19757224A1 Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation Method and apparatus for in-situ formulation of a medicinal substance solution for parenteral administration |
| 07/01/1999 | CA2318434A1 Thrombogenic polypeptide chimeras and conjugates having activity dependent upon association with tumor vascular endothelium |
| 07/01/1999 | CA2318355A1 Chimeric proteins for the treatment of diabetes |
| 07/01/1999 | CA2316323A1 Lymphotactin as an adjuvant |
| 07/01/1999 | CA2316321A1 Delivery of multiple genes to cells using plural adeno-associated viral vectors |
| 07/01/1999 | CA2316171A1 Microparticles and their therapeutic or diagnostic use |
| 07/01/1999 | CA2316015A1 Keratinocyte growth factor-2 formulations |
| 07/01/1999 | CA2315974A1 Insulin-like growth factor binding protein fragments and the utilization thereof |
| 07/01/1999 | CA2315888A1 Beta-lipotropin and uses thereof |
| 07/01/1999 | CA2315788A1 Human nucleotide pyrophosphohydrolase-2 |
| 07/01/1999 | CA2315644A1 Antagonists of g-protein-coupled receptor |
| 07/01/1999 | CA2315539A1 Compositions derived from mycobacterium vaccae and methods for their use |
| 07/01/1999 | CA2315301A1 Protein binding polypeptides |
| 07/01/1999 | CA2315300A1 Insoluble compositions for controlling blood glucose |
| 07/01/1999 | CA2315280A1 Method for quantifying denatured ldl |
| 07/01/1999 | CA2315245A1 Secreted proteins and polynucleotides encoding them |
| 07/01/1999 | CA2315037A1 Methods and compositions for inhibiting tumor cell growth |
| 07/01/1999 | CA2314905A1 Transvascular delivery of a composition to an extravascular tissue of a mammal |
| 07/01/1999 | CA2314614A1 A dna molecule encoding a mutant prepro-neuropeptide y, a mutant signal peptide, and uses thereof |
| 07/01/1999 | CA2314437A1 Mood disorder gene |
| 07/01/1999 | CA2313805A1 Method for reducing susceptibility to hiv infection |
| 07/01/1999 | CA2313804A1 Receptor tyrosine kinase, ar-1, is a regulator of angiogenesis |
| 07/01/1999 | CA2312826A1 Hemiasterlin analogs |
| 07/01/1999 | CA2311999A1 Genetic inhibition by double-stranded rna |
| 07/01/1999 | CA2311416A1 Prostate cancer gene |
| 07/01/1999 | CA2309158A1 Acellular matrix grafts: preparation and use |
| 07/01/1999 | CA2305436A1 Ace inhibitor-mmp inhibitor combinations |
| 07/01/1999 | CA2303483A1 Sag: sensitive to apoptosis gene |
| 06/30/1999 | EP0926677A2 Method and system for producing personal golf lesson video |
| 06/30/1999 | EP0926543A1 Silver halide emulsions with recombinant collagen suitable for photographic application and also the preparation thereof |
| 06/30/1999 | EP0926239A2 Beta-lipotropin and uses thereof |
| 06/30/1999 | EP0926237A2 Nucleic acid constructs for gene therapy, whose activity is influenced by inhibitors of cyclin-dependent kinases |
| 06/30/1999 | EP0926236A1 Binding partners for inhibitors of cyclin-dependent kinases and their use for inhibitor screening, diagnosis or therapy |
| 06/30/1999 | EP0926159A2 Glucagon-like peptide-1 crystals |
| 06/30/1999 | EP0925792A2 Insoluble compositions for controlling blood glucose |
| 06/30/1999 | EP0925791A1 Preventive and/or therapeutic agent for kidney diseases |
| 06/30/1999 | EP0925502A1 Diagnostic and therapeutic nucleotide or nucleoside photoaffinity compound modified antibodies, and use thereof |
| 06/30/1999 | EP0925360A1 Angiogenic factor and use thereof in treating cardiovascular disease |
| 06/30/1999 | EP0925359A1 Monoclonal antibodies against the extracellular domain of human vegf-receptor protein (kdr) |
| 06/30/1999 | EP0925358A1 Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use |
| 06/30/1999 | EP0925356A1 New antigen presenting cells, a process for preparing the same and their use as cellular vaccines |
| 06/30/1999 | EP0925309A1 Use of proteins as anti-retroviral agents |
| 06/30/1999 | EP0925308A2 Compositions and methods for treating infections using analogues of indolicidin |
| 06/30/1999 | EP0925307A1 Enzyme and dna sequence encoding same |
| 06/30/1999 | EP0925305A1 Cyclitol containing carbohydrates from human tissue which regulate lipogenic activity |
| 06/30/1999 | EP0925304A1 Cyclitol containing carbohydrates from human tissue which regulate glycogen metabolism |
| 06/30/1999 | EP0925074A1 Reversal of cancer phenotype by inhibiting expression of prostate tumor inducing gene |
| 06/30/1999 | EP0925072A2 Method for lowering cholesterol levels |
| 06/30/1999 | EP0925071A1 Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions |
| 06/30/1999 | EP0925070A1 Antifungal combination therapy |
| 06/30/1999 | EP0925069A1 Means for treating prostate hypertrophy and prostate cancer |
| 06/30/1999 | EP0925067A1 Composition and method for repairing neurological tissue |
| 06/30/1999 | EP0925059A1 Protein-lipid vesicles and autogenous vaccine comprising the same |
| 06/30/1999 | EP0925057A1 Bowman-birk inhibitor for male sexual dysfunction |
| 06/30/1999 | EP0820296A4 Analogs of growth hormone-releasing factor |
| 06/30/1999 | EP0756602B1 Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines |
| 06/30/1999 | EP0748337B1 Process for the obtention of a biological adhesive comprising fibrinogen, factor xiii and fibronectin |
| 06/30/1999 | EP0725141A4 Method of controlled genetic transformation of an animal mammary gland and a device for introducing genetic material into the mammary duct of an animal mammary gland |
| 06/30/1999 | EP0701606A4 Method of enhancing thrombolysis |
| 06/30/1999 | EP0470128B1 Active carbonates of polyalkylene oxides for modification of polypeptides |
| 06/30/1999 | CN1221452A Hybrid interferon compositions and method of use |
| 06/30/1999 | CN1221449A Modulators of TNF receptor associated factor (TRAF), their preparation and use |
| 06/30/1999 | CN1221427A Modified factor VII |
| 06/30/1999 | CN1221426A Fragments of leptin (OB protein) |
| 06/30/1999 | CN1221424A 肽衍生物 Peptide derivatives |
| 06/30/1999 | CN1221349A Cellular vaccines immunotherapeutics and methods for their preparation |
| 06/30/1999 | CN1221347A Medicament for optimising mucosal viscosity and stimulating intestinal function |
| 06/30/1999 | CN1221345A Isolated necleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof |
| 06/30/1999 | CN1221033A Oncogene- or virus-controlled expression systems |
| 06/29/1999 | US5917052 Hypoglycemic agent from cryptolepis |
| 06/29/1999 | US5917028 Polynucleotide sequence of protein involved in neurotransmitter signal transduction and cell development; diagnosis and treatment of parkinson's/huntington's diseases |
| 06/29/1999 | US5917027 Nucleic acids encoding potassium-channel proteins |
| 06/29/1999 | US5917019 The a-trfs have a particular use in counteracting the telomere shortening associated with aging and certain diseases such as ataxia telangiectasia. |
| 06/29/1999 | US5917015 Amine-containing organic group attached through a linker |
| 06/29/1999 | US5917014 Methods of treating inflammation and compositions therefor |
| 06/29/1999 | US5917013 Peptides and their use to ameliorate cell death |
| 06/29/1999 | US5916910 Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
| 06/29/1999 | US5916888 Imidazo 1,5A!pyridine derived serine protease inhibitors |
| 06/29/1999 | US5916887 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators |
| 06/29/1999 | US5916877 For detecting serine proteases in cells; enzyme inhibitors |
| 06/29/1999 | US5916876 Peptide inhibitors of leukocyte adhesion |
| 06/29/1999 | US5916875 Cell attaching as fibronectins |
| 06/29/1999 | US5916874 Method for treating liver injury |
| 06/29/1999 | US5916873 Bactericides; grampositive bacteria |
| 06/29/1999 | US5916872 Efficiency; long half-life |
| 06/29/1999 | US5916870 Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
| 06/29/1999 | US5916869 Peptide yy agonist |
| 06/29/1999 | US5916808 Hybridizing to pre-messenger rna at splice element of native intron, thus creating duplex and permitting splicing; oligonucleotide does not activate rnaase h and blocks mutant splice elements; treatment of beta-thalassemia |
| 06/29/1999 | US5916807 Inhibiting gene expression of enzyme by contacting cells with synthetic antisense agent; used as anticarcinogenic/antiproliferative/antiinflammatory agents |
| 06/29/1999 | US5916805 Antithrombotic agent and anti-von Willebrand factor monoclonal antibody |
| 06/29/1999 | US5916803 Target cell-specific non-viral vectors for inserting genes into cells, pharmaceutical compositions comprising such vectors and their use |